Summary of Key Information:
Reporting Period (Quarter/Year): Quarter and Half Year ended September 30, 2026
Nature of Filing / Announcement: Regulatory filing under SEBI Listing Regulations 30 & 33 for financial results
Audit Opinion:
Qualified Opinion - Modified conclusion issued by statutory auditors M/s PKF Sridhar and Santhanam LLP
Key Financial Highlights [₹ in millions]:
Consolidated Results:
Quarter Ended September 30, 2026:
- Revenue from Operations: ₹1,212.66 (QoQ +11.3%, YoY +23.3%)
- Total Income: ₹1,240.44
- Net Profit: ₹75.98 (QoQ -31.7%, YoY -30.8%)
- EPS: ₹1.40 (Basic and Diluted)
- Other Equity: ₹4,059.36
- Cash and Cash Equivalents: ₹377.73
- Debt: Short-term ₹4.03, Long-term ₹19.76
Half Year Ended September 30, 2026:
- Revenue from Operations: ₹2,302.01 (YoY +7.7%)
- Total Income: ₹2,367.96
- Net Profit: ₹187.27 (YoY -22.1%)
- EPS: ₹3.43 (Basic and Diluted)
Standalone Results:
Quarter Ended September 30, 2026:
- Revenue from Operations: ₹1,199.87 (QoQ +8.7%, YoY +23.8%)
- Total Income: ₹1,227.28
- Net Profit: ₹121.34 (QoQ +54.9%, YoY +13.5%)
- EPS: ₹2.21 (Basic and Diluted)
- Other Equity: ₹3,954.32
- Cash and Cash Equivalents: ₹129.19
- Debt: Short-term ₹4.03, Long-term ₹19.76
Half Year Ended September 30, 2026:
- Revenue from Operations: ₹2,303.64 (YoY +15.3%)
- Total Income: ₹2,353.34
- Net Profit: ₹238.90 (YoY -27.7%)
- EPS: ₹4.35 (Basic and Diluted)
Segment-wise Performance:
The Group operates only in one Operating Segment - "Speciality Chemicals" as per Ind AS 108, hence no segment reporting required.
Corporate Actions:
No dividend declarations, share splits, bonus issues, buybacks, or capital structure changes announced.
Other Significant Information:
IPO Proceeds Utilization (as of September 30, 2026):
Total IPO proceeds: ₹2,353.17 million (net of issue expenses: ₹2,118.29 million)
| Purpose | Proposed | Utilized upto Jun-26 | Utilized Jul-Sep-26 | Unutilized |
| Egypt subsidiary capex | ₹677.21M | ₹279.60M | ₹152.78M | ₹244.83M |
| Palghar facility capex | ₹712.61M | ₹678.28M | ₹18.92M | ₹15.41M |
| Working capital | ₹300.00M | ₹274.01M | ₹10.41M | ₹15.58M |
| General corporate | ₹428.47M | ₹427.43M | ₹1.04M | ₹0.00M |
| Total | ₹2,118.29M | ₹1,659.32M | ₹183.15M | ₹275.82M |
Unutilized funds temporarily invested in fixed deposits with scheduled commercial banks.
Subsidiary Information:
Consolidation includes 5 subsidiaries:
- Platinum Global Additives Private Limited
- Platinum Oleo Chemicals Private Limited
- M/s. Platinum Polymers & Additives (Partnership firm)
- Platinum Stabilizers Egypt LLC
- Rivadu Lifesciences Private Limited
3 subsidiaries with total assets of ₹1,215.10 million were reviewed by other auditors
2 subsidiaries with total assets of ₹101.67 million were not reviewed by their auditors
Cash Flow Highlights (Consolidated H1 FY27):
- Net cash from operating activities: ₹234.78 million
- Net cash used in investing activities: ₹437.13 million (mainly capex of ₹548.75 million)
- Net cash used in financing activities: ₹54.82 million
- Net decrease in cash: ₹257.17 million
Balance Sheet Position (Consolidated as of September 30, 2026):
- Total Assets: ₹5,692.59 million
- Total Equity: ₹4,704.74 million
- Property, Plant and Equipment: ₹1,255.19 million
- Capital Work-in-progress: ₹222.54 million
- Inventories: ₹910.34 million
- Trade Receivables: ₹1,129.38 million